When the kidneys are damaged—after surgery, cardiac arrest, or as a side effect of certain medications—doctors often face one ...
1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...
Third quarter performance driven by strong portfolio royalty revenue growth of 47%2025 full year revenue guidance increased to $225 million - ...
Three years ago, the FDA found so many violations at a Nephron Pharmaceuticals manufacturing facility that the U.S. regulator admitted in a warning letter the issues were so numerous they couldn’t all ...
Despite multiple warnings from the Food and Drug Administration about its manufacturing processes, Nephron Pharmaceuticals, one of the largest employers in Lexington, has continued to face federal ...
The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...
MedPage Today on MSN
Two Kidney Function Measures Are Not Always Aligned With Each Other
HOUSTON -- Two commonly used kidney function tests had a large degree of disagreement and were linked with serious health outcomes in patients with chronic kidney disease (CKD), according to a ...
A research team at the University of Pittsburgh, led by Dr. Anne Robertson and PhD candidate Fatemeh Azari, discovered that the bladder does not simply inflate like a balloon when it fills. Instead, ...
These findings underscore the limitations of relying on proteinuria alone to assess LN treatment success and demonstrate the clinical utility of biomarker-guided risk stratification.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback